ISKJ Stock Overview
Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Public Joint-Stock Company "Human Stem Cells Institute" Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₽59.54 |
| 52 Week High | ₽177.00 |
| 52 Week Low | ₽52.52 |
| Beta | 1.41 |
| 1 Month Change | 0% |
| 3 Month Change | 1.43% |
| 1 Year Change | -32.86% |
| 3 Year Change | 391.66% |
| 5 Year Change | 388.03% |
| Change since IPO | 306.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| ISKJ | RU Biotechs | RU Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | -0.8% |
| 1Y | -32.9% | 10.4% | 1.8% |
Return vs Industry: ISKJ underperformed the Russian Biotechs industry which returned -10.3% over the past year.
Return vs Market: ISKJ exceeded the Russian Market which returned -38.2% over the past year.
Price Volatility
| ISKJ volatility | |
|---|---|
| ISKJ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in RU Market | 9.7% |
| 10% least volatile stocks in RU Market | 2.4% |
Stable Share Price: ISKJ has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ISKJ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Prikhodko Viktorovich | hsci.ru |
Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation.
Public Joint-Stock Company "Human Stem Cells Institute" Fundamentals Summary
| ISKJ fundamental statistics | |
|---|---|
| Market cap | ₽4.29b |
| Earnings (TTM) | ₽16.94m |
| Revenue (TTM) | ₽1.14b |
253.1x
P/E Ratio3.7x
P/S RatioIs ISKJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISKJ income statement (TTM) | |
|---|---|
| Revenue | ₽1.14b |
| Cost of Revenue | ₽424.68m |
| Gross Profit | ₽719.25m |
| Other Expenses | ₽702.31m |
| Earnings | ₽16.94m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 62.88% |
| Net Profit Margin | 1.48% |
| Debt/Equity Ratio | 103.9% |
How did ISKJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/05 04:54 |
| End of Day Share Price | 2022/07/08 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Public Joint-Stock Company "Human Stem Cells Institute" is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|